Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic Analysis of Human Serum Antibody Repertoire Response to Influenza Vaccine

ABSTRACT: Proteomic profiling of serum antibody repertoire response to FluZone trivalent influenza vaccine in four healthy human subjects. Dataset consists of collected pre-vaccination (Day 0) and post-vaccination (Days 28 and 180) serum IgG samples enriched by affinity chromatography against individual monovalent inactivated components of the 2011-2012 trivalent vaccine (H1 A/California/07/2009 X-179A, H3 A/Victoria/210/2009, and B/Brisbane/60/2008).

INSTRUMENT(S): LTQ Orbitrap Velos

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: George Georgiou

PROVIDER: MSV000080184 | MassIVE |

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Similar Datasets

Longitudinal proteomic analysis of influenza HA-reactive IgG antibody repertoire over multiple years and repeated vaccinations

Project description:Longitudinal proteomic analysis of H1N1 A/California/7/2009 (CA09) hemagglutinin (HA)-reactive serum IgG antibody repertoire over 5 years and multiple (yearly) vaccinations (both pre- and post-vaccination samples) in a donor. Dataset consists of steady-state (pre-vaccination at day 0) and peak-response (2-3 weeks post-vaccination) serum IgG samples enriched by affinity chromatography against hemagglutinin protein from H1 A/California/7/2009.

2018-11-08 | MSV000083120 | MassIVE

Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans

Project description:Proteomic analysis of serum IgG antibody repertoire against influenza vaccine H1 (H1N1 A/California/7/2009) and H3 (H3N2 A/Texas/50/2012) in young, middle-aged, and elderly donors vaccinated with Fluzone 2013-14/14-15. Dataset consists of peak-response (days 21-28 post-vaccination) serum IgG samples eluted by affinity chromatography against H1 and H3 vaccine or hemagglutinin and the flow-throughs.

| MSV000086108 | MassIVE

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_2_iga)

Project description:Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and hetero-subtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. Adjuvanted vaccine was also associated with the elicitation of stalk directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.

2022-07-01 | GSE202383 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_1_igg)

2022-07-01 | GSE202382 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_1_iga)

2022-07-01 | GSE202380 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_4_iga)

2022-07-01 | GSE202389 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_3_igg)

2022-07-01 | GSE202388 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_3_iga)

2022-07-01 | GSE202387 | GEO

The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination (probing_2_igg)